Patrick Daly

Articles by Patrick Daly

Valentina Restrepo, MDHematology | June 3, 2024
Dr. Restrepo discusses coagulation and issues in coagulopathy risk screening in patients who have venous malformations.
View More
Konstanze Döhner, MDHematology | June 10, 2024
Konstanze Döhner, MD, met to discuss the background and ongoing progress of the EHA Lighting the Flame program.
Patrick DalySickle Cell Disease | May 2, 2024
Phase III data from the CLIMB SCD-121 trial verified the efficacy of exa-cel in eliminating vaso-occlusive crises in SCD.
Patrick DalyHemophilia | April 29, 2024
The US FDA has approved fidanacogene elaparvovec-dzkt, a gene therapy for adults with hemophilia B.
Patrick DalyAnemia | April 26, 2024
Oral and intravenous iron supplementation effectively treated restless legs syndrome in patients with iron deficiency anemia.
Patrick DalySickle Cell Disease | April 23, 2024
Etavopivat was safe and increased hemoglobin, decreased hemolysis, and improved red blood cells in patients with SCD.
Patrick DalySickle Cell Disease | April 23, 2024
Dr. Vadivelan shared her study on pituitary and pancreatic iron deposition in patients with SCD at the 2024 ASPHO Conference.
Patrick DalySickle Cell Disease | April 19, 2024
Stuart Orkin, MD, has been named as one of Time’s 100 Most Influential People of 2024 for his work in hemoglobin research.
Patrick DalyAnemia | April 17, 2024
Intravenous iron was safe and effective in pediatric patients with iron deficiency anemia and inflammatory bowel disease.
Patrick DalyAnemia | April 15, 2024
Delaying treatment for SAA until genetic testing for IBMFS may be detrimental in patients with negative workup and history.
Yaw Ansong-Ansongton, MDSickle Cell Disease | April 12, 2024
Dr. Ansong-Ansongton shared what National Minority Health Month and Celebrate Diversity Month mean to him at ASPHO 2024.
Yaw Ansong-Ansongton, MDSickle Cell Disease | April 9, 2024
Dr. Ansong-Ansongton described data on the impact of abnormal mitochondrial retention and cold in red blood cells in SCD.
Erica Mamauag, MDHemophilia | April 9, 2024
Dr. Mamauag details her study on the need for factor VIII infusions in patients with tolerized hemophilia A on emicizumab.
Patrick DalyAnemia | April 5, 2024
The MAA for RP-L102, an investigational gene therapy for Fanconi anemia, has been approved by the EMA.
Anjali Sharathkumar, MDAnemia | April 5, 2024
Dr. Sharathkumar shared data from her 2024 ASPHO presentation on romiplostim in children with severe aplastic anemia and MDS.
Patrick DalyAnemia | April 3, 2024
The European Commission approved an expanded indication for luspatercept as first-line therapy for anemia in lower-risk MDS.
Patrick DalySickle Cell Disease | April 4, 2024
A standardized, local TCD supported by central quality review was implemented effectively in resource-constrained settings.
Patrick DalyPNH | April 2, 2024
The US FDA has approved danicopan as an add-on therapy in patients with PNH and EVH on standard-of-care C5 inhibitor therapy.
Patrick DalyAnemia | March 29, 2024
The US FDA has approved vadadustat to treat anemia due to CKD in adults who have been on dialysis for at least three months.
Patrick DalyHemophilia | April 1, 2024
The US FDA has approved an expanded indication for IXINITY to control bleeding in all patients with hemophilia B.